Wenyang Shi

Wenyang Shi

Auto-generated profile, based on publicly available information

Wenyang Shi

Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
YSYizhe Sun
Yizhe Sun
AFAndrea Rodgers Furones
Andrea Rodgers Furones
OGOkan Gultekin
Okan Gultekin
SKShruti Khare
Shruti Khare
SNShi Yong Neo
Shi Yong Neo
DSDhifaf Sarhan
Dhifaf Sarhan
Adaptive NK (aNK) cells have emerged as a subset of NK cells with memory-like properties and specific cytotoxicity, offering promising therapeutic potential in cancer immunotherapy. In this study, we explored the role of aNK cells in high-grade serous ovarian cancer, focusing on their ability to establish tumor-specific immune memory and effectively target autologous tumors. Through a combination of in silico, in vitro, and ex vivo approaches, we demonstrated that aNK cells, in contrast to conventional NK cells, exhibit recall responses, specific cytotoxicity, and preferential infiltration into the tumor microenvironment. Our data revealed that aNK cells interact with dendritic cells within the tumor microenvironment via the HLA-E/NKG2C axis and CXCR2 signaling, contributing to their memory formation and tumor-targeting capabilities. These findings suggest that aNK cells could serve as potent agents in NK cell–based immunotherapies, particularly in solid tumors such as high-grade serous ovarian cancer, in which they resist immunosuppressive signals and maintain robust antitumor activity. This study provides new insights into the adaptive-like properties of aNK cells, underscoring their potential for advancing cancer immunotherapy strategies.

1 March 2026 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
MWMeng Wan
Meng Wan
TZTangwu Zhong
Tangwu Zhong
WSWenyang Shi
Wenyang Shi
JSJianyu Shen
Jianyu Shen
WZWei Zhang
Wei Zhang
YSYizhe Sun
Yizhe Sun
Chemoradiotherapy (CRT) induces tumor cell death and remodeling of the tumor immune microenvironment. Adaptive natural killer (aNK) cells, initially characterized in chronic viral infection, are now recognized as important in solid tumors, contributing to antitumor immunity and immune memory. However, the dynamics of aNK cell response to CRT and the regulatory mechanisms behind their activation are not well understood. We analyzed single-cell RNA sequencing data from cervical cancer patients before CRT, after the first CRT fraction, and after the second fraction. We found that CRT markedly enriched aNK cells, with increased cytotoxicity and enhanced virus-defending programs. Among the differentially expressed genes, the transcription factor PRDM1 (PR/SET domain 1, also known as BLIMP-1:B lymphocyte-induced maturation protein 1) was consistently up-regulated in aNK cells after both rounds of CRT. To explore the potential role of PRDM1, we performed in silico perturbation analyses using scTenifoldKnk and CellOracle. These computational simulations predicted reduced effector-associated programs and perturbed metabolic networks following PRDM1 disruption in aNK cells. Moreover, PRDM1 perturbation altered inferred cellular trajectories, opposing the transcriptional shift toward an adaptive NK-associated state, suggesting that PRDM1 may contribute to maintenance of aNK-associated identity and functional features in the CRT-conditioned tumor microenvironment. These findings identify PRDM1 as a candidate regulator associated with aNK cell enrichment, activation-related remodeling, and trajectory-associated changes following CRT, providing insight into immune remodeling during CRT and highlighting PRDM1 as a promising regulatory candidate for future investigation in radiotherapy-induced antitumor immunity.

2 July 2025
Verified
Other
Open access
YSYizhe Sun
Yizhe Sun
AFAndrea Rodgers Furones
Andrea Rodgers Furones
OGOkan Gultekin
Okan Gultekin
SKShruti Khare
Shruti Khare
SNShi Yong Neo
Shi Yong Neo
DSDhifaf Sarhan
Dhifaf Sarhan
Adaptive NK (aNK) cells have emerged as a subset of NK cells with memory-like properties and specific cytotoxicity, offering promising therapeutic potential in cancer immunotherapy. In this study, we explored the role of aNK cells in high-grade serous ovarian cancer, focusing on their ability to establish tumor-specific immune memory and effectively target autologous tumors. Through a combination of in silico, in vitro, and ex vivo approaches, we demonstrated that aNK cells, in contrast to conventional NK cells, exhibit recall responses, specific cytotoxicity, and preferential infiltration into the tumor microenvironment. Our data revealed that aNK cells interact with dendritic cells within the tumor microenvironment via the HLA-E/NKG2C axis and CXCR2 signaling, contributing to their memory formation and tumor-targeting capabilities. These findings suggest that aNK cells could serve as potent agents in NK cell–based immunotherapies, particularly in solid tumors such as high-grade serous ovarian cancer, in which they resist immunosuppressive signals and maintain robust antitumor activity. This study provides new insights into the adaptive-like properties of aNK cells, underscoring their potential for advancing cancer immunotherapy strategies.